Table 1.
Kidney Recipient and Donor Demographics and Clinical Factors in Recipients Receiving Tacrolimus
| Young Age (18–34 yrs, n=266) | Middle Age (35–64 yrs, n=1425) | Old Age (65–84 yrs, n=276) | |
|---|---|---|---|
| Recipient age, median (range) | 29.3(18.4–35.0) | 51.1(35.0–64.9) | 68.5 (65.1–83.8) |
| Recipient gender, male | 153 (57.5%) | 906 (63.6%) | 178 (64.5%) |
| Recipient African American | 72 (27.1%) | 284 (19.9%) | 18 (6.5%) |
| Recipient weight (kg), median (range) | 71.8 (38.6–152.0) | 81.6 (37.3–164.2) | 81.0 (44.2–130.2) |
| Prior kidney transplant | 56 (21.1%) | 217 (15.2%) | 16 (5.8%) |
| Primary cause of kidney failure | |||
| diabetes mellitus | 48 (18.1%) | 462 (32.4%) | 84 (30.4%) |
| glomerulonephritis | 85 (32.0%) | 301 (21.1%) | 45 (16.3%) |
| polycystic kidney disease | 9 (3.4%) | 215 (15.1%) | 30 (10.9%) |
| hypertension | 27 (10.2%) | 195 (13.7%) | 49 (17.8%) |
| others | 82 (30.8%) | 218 (15.3%) | 54 (19.6%) |
| unknown | 15 (5.6%) | 34 (2.4%) | 14 (5.1%) |
| Diabetes at time of transplant | 52 (19.6%) | 592 (41.6%) | 119 (43.1%) |
| SPK1 | 24 (9.0%) | 128 (9.0%) | 1 (0.4%) |
| Donor age, median (range) | 36.9 (7.5–63.9) | 42.3 (1.7–70.9) | 48.3 (10.4–76.7) |
| Donor gender, male | 126 (47.4%) | 690 (48.6%) | 120 (43.8%) |
| Living donor | 175 (65.8%) | 791 (55.5%) | 168 (61.1%) |
| Dialysis after transplantation2 | 19 (7.1%) | 134 (9.4%) | 23 (8.3%) |
| Calcium channel blocker use3 | 1764 (40.3%) | 10585 (42.0%) | 2259 (46.0%) |
| Prophylactic antiviral use 3 | 2261 (51.7%) | 13652 (54.5%) | 2520 (51.4%) |
| ACE Inhibitor use3 | 623 (14.2) | 3565 (14.2%) | 665 (13.5%) |
| Steroids use3 | 2859 (65.4%) | 14623 (58.5%) | 3464 (71.0%) |
1
simultaneous pancreas kidney transplant
2
one or more dialysis sessions within first 30 days posttransplant in living and deceased subjects
3
drug from this class use at the time of trough measurement
4
calcium channel blocker was present at time of trough measurement; primarily amlodipine and diltiazem.